Resources | NITAG RESOURCE CENTER

2024 ∙ SAGE

Development of WHO immunization policy and strategic guidance

2024 ∙ Louise Henaff, Dace Zavadska, Mario Melgar, Johanna Fihman, Christoph Steffen, Joachim Hombach

The role of NITAGs in government decisions on vaccine use: insights from the Fifth Global NITAG Network meeting

2024

Meningococcal vaccines: WHO position paper on the use of multivalent meningococcal conjugate vaccines in countries of the African meningitis belt, January 2024

2023 ∙ Eiden, Amanda L. Barratt, Jane Nyaku, Mawuli K.

A review of factors influencing vaccination policies and programs for older adults globally

2023 ∙ Vraga, Emily K. Brady, Sonya S. Gansen, Chloe Khan, Euna Mehnaz Bennis, Sarah L. Nones, Madalyn Tang, Rongwei Srivastava, Jaideep Kulasingam, Shalini

A review of HPV and HBV vaccine hesitancy, intention, and uptake in the era of social media and COVID-19

2023 ∙ Angulo, F. J. Zhang, P. Halsby, K. Kelly, P. Pilz, A. Madhava, H. Moïsi, J. C. Jodar, L.

A systematic literature review of the effectiveness of tick-borne encephalitis vaccines in Europe

2023 ∙ Xu, K. Wang, Z. Qin, M. Gao, Y. Luo, N. Xie, W. Zou, Y. Wang, J. Ma, X.

A systematic review and meta-analysis of the effectiveness and safety of COVID-19 vaccination in older adults

2023 ∙ Tavabe, Nilay Rezaei Kheiri, Soleiman Dehghani, Mohsen Mohammadian-Hafshejani, Abdollah

A Systematic Review and Meta-Analysis of the Relationship between Receiving the Flu Vaccine with Acute Cerebrovascular Accident and Its Hospitalization in the Elderly

2023 ∙ Chen, S. Wei, W. Huang, F. Wang, J. Li, X. Gen, Z. Gao, F. Dong, T. Wei, P. Yang, X. Miao, F.

A systematic review and meta-analysis of the seroconversion rates and adverse effects of COVID-19 mRNA vaccine and COVID-19 viral vector vaccine in kidney transplant recipient patients

2023 ∙ Mohammed, H. Pham-Tran, D. D. Yeoh, Z. Y. M. Wang, B. McMillan, M. Andraweera, P. H. Marshall, H. S.

A Systematic Review and Meta-Analysis on the Real-World Effectiveness of COVID-19 Vaccines against Infection, Symptomatic and Severe COVID-19 Disease Caused by the Omicron Variant (B.1.1.529)